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A B cell-specific growth substance (BGS) was isolated
from the slime layer of Bacillus licheniformis E1. Unlike
LPS, the BGS was not affected by polymixin B, an
inhibitor of LPS, or by TLR4, and resulted in the growth
of B cells. When BALB/c mice were treated with the BGS,
the B cell population was found to increase in both the
bone marrow and the spleen, with a marked increase after
24 h in the bone marrow and after 48 h in the spleen.
When using antibodies to B cell lineage-restricted surface
molecules to analyze the B cell population changes resulting
from treatment with the BGS, an increase in immature B
cells (IgM
+
 and AA4.1
+
) and mature B cells (IgM
+
 and
IgD
+
) was found in the bone marrow 24 h after treatment
with the BGS, whereas a decrease in mature B cells and
increase in IgG
+
 B cells were found in the spleen. When the
BGS and OVA antigen were injected into the peritoneal
cavity of BALB/c mice, this resulted in a high OVA-
specific antibody titer in the sera, similar to that induced
by aluminum hydroxide. Therefore, it is anticipated that
the mass production of the BGS by B. licheniformis E1
could be used for studies of B cells in immunology, and
contribute to the development of a new adjuvant for
vaccine manufacture.
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Immunomodulators are substances that can affect the
host immune response by increasing or suppressing the
growth, differentiation, and activities of immune cells [12,
18]. Proteins, glycoproteins, peptides, lipopolysaccharides
(LPS), and lipid derivatives [33] are all well-known
immunomodulators. Although some of these substances
are derived from animals and plants, they are mainly produced
by microorganisms.
Polysaccharide A (PS A) [34], β-(1-3)-glucans [25, 35],
mannan [36], krestin (PSK), polysaccharopeptide (PSP)
[23], and hyaluronic acid (HA) [30] are some of the
currently known immunomodulators derived from microbes,
and such polymers unusually increase the activities of T
cells or antigen-presenting cells (APCs) [33].
Some substances function as T cell-independent antigens in
the host immune system that differentiate B cells as short-lived
effector cells with no immunologic memory by stimulating B
cells without any help from T cells, and also function to induce
the production of low-affinity IgM and IgG antibodies [1, 31].
Known examples include LPS from Gram-negative bacteria,
the immunostimulating factor (ISTF) of Actinobacillus
actinomycetemcomitans, macrophage-activating lipopeptide-
2 (MALP-2) of Mycoplasma fermentans, and outer surface
lipoprotein A (OspA), which is a lipoprotein from Borrelia
burgdorferi. LPS is a typical bacterial B cell mitogen that
induces the differentiation of B cells and also promotes the
expression of IgM on the surface of B cells [21]. Meanwhile,
ISTF not only proliferates B cells and APCs, but also
induces the production of IL-6 and tumor necrosis factor-α
(TNF-α) [17], MALP-2 increases the proliferation and
differentiation of B cells through Toll-like receptor 2 (TLR2)
in a T cell-independent manner [5], and OspA is known to
proliferate B cells through CD40/CD40L interaction [31].
In a previous report, the current authors separated a
B cell-specific growth substance from a slime layer of
Bacillus licheniformis E1 [8]. This study investigated the
impact of the growth substance on the different stages of B
cell differentiation, while also evaluating the effectiveness
of the growth substance as an adjuvant.
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MATERIALS AND METHODS
Animals
BALB/c, C3H/HeJ, and C3H/HeN female mice between 6 and 7
weeks of age were purchased from Orientbio (Seoul, Korea) and
Central Lab. Animal (Seoul, Korea). The animals were maintained
and used in accordance with guidelines prepared by Yonsei
University College of Medicine (Seoul, Korea), which has been
fully accredited by the Association for Assessment and Accreditation
of Laboratory Animal Care, International (AAALAC) for the care
and use of laboratory animals.
Reagents
The aluminum hydroxide (Al), Freund’s complete adjuvant (FCA),
Freund’s incomplete adjuvant (FICA), LPS (from Escherichia coli,
serotype 0111:B4), ovalbumin (OVA), peroxidase substrate, and
polymixin B (PMB) were all purchased from Sigma-Aldrich
(Steinheim, Germany), and the EZ-link Sulfo-NHS-LC-biotinylation
kit used to biotinylate the OVA was purchased from Pierce
(Rockford, IL, U.S.A.).
Antibodies
The antibodies used for the cell staining and FACS analysis were as
follows: phycoerythrin (PE) anti-mouse CD45R/B220, fluorescein
isothiocyanate (FITC) anti-mouse CD3, FITC anti-mouse CD25 (IL-
2R), FITC anti-mouse CD117 (c-kit), FITC anti-mouse IgM (BD
Pharmingen, SanDiego, CA, U.S.A.), FITC anti-mouse IgG (Vector
Laboratories, Burlingame, CA, U.S.A.), PE anti-mouse IgD, and PE
anti-mouse C1qRp (AA4.1) (eBioscience, Burlingame, CA, U.S.A.).
The antibodies used for the ELISA were as follows: purified anti-
mouse IgG, horseradish peroxidase (HRP)-conjugated anti-mouse
IgG (BD Pharmingen), affiniPure rabbit anti-mouse IgM and IgG
Abs (ImmunoResearch Laboratories, West Grove, PA, U.S.A.),
purified mouse IgM and IgG, HRP-conjugated goat anti-mouse IgM
and IgG (Southern Biotechnology Associates, Birmingham, AL,
U.S.A.), and HRP-conjugated anti-biotin (Vector Laboratories).
Purification of BGS from Bacillus licheniformis E1
The purification of the concentrate from B. licheniformis E1 was
performed as previously described [8]. Briefly, the B. licheniformis
E1 was cultured in a brain heart infusion (BHI; Difco, Becton
Dickinson, Sparks, MA, U.S.A.) broth on a shaker at 37
o
C for 48 h.
The cultured supernatant was then spun down at 10,000 ×g at 4
o
C
for 1 h, and then the harvested supernatant was boiled at 100
o
C for
30 min and spun down again in the same way as described above.
The supernatant was concentrated using a DIAFLO ultrafiltration
membrane (Filter code: YM 100; Millipore, Bedford, MA, U.S.A.).
Five ml of the concentrate was then applied to a DEAE Sepharose
Fast Flow column (25×330 mm) (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden) previously equilibrated with a 0.05 M phosphate
buffer (pH 7.4), and the column eluted with a linear gradient of
0.0-1.0 M NaCl in the phosphate buffer at a flow rate of 2 ml/min.
Five ml of each fraction was collected and monitored at 280 nm,
and their activities measured using a BALB/c mouse B cell
proliferation assay. Those elutes showing mouse B cell proliferation
activity were pooled and concentrated using the same ultrafiltration
membrane. Thereafter, 1 ml of the concentrate was subjected to a
Sephacryl S-500 column (16×900 mm) (GE Healthcare Bio-Sciences
AB) previously equilibrated with the phosphate buffer and eluted
with the same buffer at a flow rate of 1 ml/min. Three ml of each
fraction was collected and monitored at 280 nm. Those elutes
showing mouse B cell proliferation activity were pooled and
concentrated using the same ultrafiltration membrane. The concentrate
was again subjected to a Superose TM 6HR column (GE Healthcare
Bio-Sciences AB), and the fractions monitored at 214 nm. The
fractions at the peak were collected, pooled, concentrated, and
freeze-dried. The resulting concentrate produced by B. licheniformis
E1 is hereinafter referred to as the B cell-specific growth substance
(BGS).
Isolation of Mouse T and B Cells
The lymphocytes were obtained from the mice spleens. A single cell
suspension was prepared by gently teasing a spleen between two
glass slides, and the red blood cells were lysed using an ACK lysis
buffer (155 mM NH
4
Cl, 10 mM KHCO
3
, and 0.1 mM EDTA).
To isolate the T cells, the splenocytes were incubated in a MACS
buffer (PBS containing 0.5% bovine serum albumin and 2 mM
EDTA) with a biotin-antibody cocktail (biotin-conjugated monoclonal
antibodies against CD45R, CD49b, CD11b, and Ter-119; Miltenyl
Biotec, Auburn, CA, U.S.A.) for 10 min at 4
o
C, washed, and
incubated with anti-biotin MicroBeads (Miltenyl Biotec) for 15 min
at 4
o
C, according to the procedures provided by the manufacturer.
The cells were then applied to a magnetic column (Miltenyl Biotec),
and the effluent was collected and washed in an RPMI 1640 medium
supplemented with 2 mM L-glutamine, 2.2 mM sodium bicarbonate,
100 U/ml penicillin, and 100 µg/ml streptomycin (Gibco BRL,
Grand Island, NY, U.S.A.).
To isolate the B cells, biotin-conjugated monoclonal antibodies
against CD43, CD4, and Ter-119 (Miltenyl Biotec) were used.
Splenocyte Proliferation Assay
The activity of the purified BGS was measured based on the
proliferation of the splenocytes from the BALB/c mice. The
fractionated T or B cells in a complete medium supplemented with
RPMI 1640 and 10% heat-inactivated fetal calf serum (2.5×
10
5
cells/well) were plated in 96-well round-bottomed microtiter
plates (Corning, NY, U.S.A.). Fifty µl of the purified BGS was then
added to each well and the plates were cultured for 48 h. The cell
proliferation was measured using 6 h of 
3
H-thymidine (
3
H-TdR,
New England Nuclear, Boston, MA, U.S.A.) incorporation.
Immunization
To induce a BGS-specific immune response, BALB/c mice were
injected once intraperitoneally (i.p.) (day 0) with the purified BGS
(25 µg/mouse). The mice were then sacrificed 1, 2, and 3 d after the
i.p. immunization, and cell suspensions from the spleen and bone
marrow from each group of mice used for FACS analysis.
For OVA immunization, BALB/c mice were injected with an
initial intradermal (i.d.) immunization of OVA (100 µg/mouse)
mixed with one of the following adjuvants: FCA adjuvant (100 µl/
mouse), Al (20 µg/mouse), or the BGS (25 µg/mouse). The mice
were then intradermally boosted with OVA (100 µg/mouse) mixed
with FICA (100 µl/mouse), Al (20 µg/mouse), or the BGS (25 µg/
mouse) 1, 2, and 3 weeks after the initial immunization. One week
after the last immunization, blood was harvested through the vena
cava of each mouse, and the sera stored at -20
o
C until the ELISA.
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Isolation of Bone Marrow Cells
Bone marrow cells from BALB/c mice were flushed out of the femurs
with an ice-cooled complete medium using a 10-ml syringe with a 21-
gauge needle. The red blood cells were depleted using an ACK lysis
buffer, and the bone marrow cells washed with an RPMI 1640 medium.
Thymidine Incorporation Assay
A total of 1×10
6
cells/ml were cultured in 200-µl volumes in 96-
well round-bottom plates. The cells were cultured for 48 h and
pulsed with 1 µCi per well of 
3
H-TdR for the last 8 h before
determining the 
3
H-thymidine incorporation.
FACS Analysis
For the cytometric analysis of the bone marrow cells, splenocytes,
and MACS-purified T or B cell suspensions, the cells were
incubated with antibodies labeled with FITC and/or PE in a FACS
buffer (PBS, 1% FCS, 0.05% sodium-azide) for 30 min on ice, and
then washed twice with the same FACS buffer. The data were
acquired using a FACSCalibur (Becton Dickinson, San Jose,
U.S.A.) and analyzed using CellQuest software (Becton Dickinson).
ELISA Methods
The total IgM and IgG levels were measured using a capture-
ELISA. Ninety-six-well ELISA plates (Nunc, Copenhagen, Denmark)
were coated with 100 µl/well of affiniPure rabbit anti-mouse IgM
(1 µg/ml) or IgG (2 µg/ml) Ab for 24 h and blocked with 150 µl of
PBS containing 10% BSA for 2 h at room temperature. After
washing the plates three times with PBS containing 0.05% Tween
20 (PBST), the BALB/c mouse sera diluted with PBS containing
10% BSA (100 µl/well) were added and incubated for 1 h. The
plates were then washed five times, and 100 µl of 1/1,500 HRP-
conjugated goat anti-mouse IgM or IgG Ab was added to each well.
After incubating the plates at room temperature for 1 h, they were
washed five times with PBST and reacted with a peroxidase
substrate at 37
o
C for 30 min. The reaction was stopped by the
addition of 2 N H
2
SO
4
 and the optical density (OD) at 450 nm read
using an ELISA plate reader. The standard curves for IgM and IgG
Ab were plotted using purified mouse IgM and IgG, respectively.
The OVA-specific IgG levels were measured using a capture-
ELISA. The plates were coated with 100 µl/well of purified anti-
mouse IgG mAb (2 µg/ml) for 24 h and blocked with 150 µl of PBS
containing 10% BSA for 2 h at room temperature. After washing
the plates three times with PBST, the BALB/c mouse sera diluted
with PBS containing 10% BSA (100 µl/well) were added and
incubated for 1 h. One hundred µl per well of biotinylated OVA
(10 µg/ml) was then added and the incubation continued for 1 h at
room temperature. The plates were then washed five times, and
100 µl of 1/1,500 HRP-conjugated goat anti-biotin mAb was added
to each well. After incubating the plates at room temperature for
1 h, they were washed five times with PBST and reacted with a
peroxidase substrate at 37
o
C for 30 min. The reaction was stopped
by the addition of 2 N H
2
SO
4
 and the OD at 450 nm read using an
ELISA plate reader.
Statistical Analysis
All the experiments were performed based on three separate trials and
representative data are presented. All the data are expressed as the
mean±SD (n=3). The differences were analyzed using the Student’s
t-test and the results considered significant with a p-value <0.05.
RESULTS
Effect of BGS on Proliferation of Mouse Spleen
Lymphocytes
Since LPS is a well-known B cell mitogen [15, 22], the
effect of the BGS on the proliferation of BALB/c mice
lymphocytes was compared with the effect of LPS.
Lymphocytes isolated from the spleens of BALB/c mice were
treated with various doses of the BGS or LPS, incubated for
48 h, and then measured using a 
3
H-TdR incorporation
assay. As shown in Fig. 1, the BGS and LPS both induced
splenocyte proliferation, and their splenocyte proliferation
Fig. 1. Effect of BGS on proliferation of splenocytes.
Splenocytes (2×10
5
cells/200 µl) from BALB/c mice were incubated with
various concentrations (horizontal axis) of the BGS or LPS for 48 h,
followed by a 6 h 
3
H-TdR incorporation assay. Each value represents the
mean±SD of three trials.
Fig. 2. BGS induced proliferation of B cells in vitro.
Splenic B or T cells were cultured for 48 h with the BGS (10 µg/ml) or
LPS (5 µg/ml), and the cell proliferation was measured based on the 6 h
3
H-TdR incorporation. Each value represents the mean±SD of three trials.
*, Statistical significance compared with “LPS” (p=0.2004).
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activities were shown to be dose-dependent. The optimized
concentration doses of the BGS and LPS for mouse
splenocyte proliferation were 10 mg/ml and 5 mg/ml,
respectively.
To determine which splenocytes were proliferated in
response to the BGS and LPS, the T and B cell proliferation
responses were measured using a 
3
H-TdR incorporation
assay. The T and B cells were treated with the optimized
concentration of the BGS or LPS, and then incubated for
48 h. As expected, the BGS and LPS both induced B cell
proliferation, whereas neither affected the T cell proliferation.
The B cell proliferation measurements for the BGS and
LPS were 18.66±1.80 and 20.15±2.19 kcpm, respectively;
however, the statistical difference between the two was
insignificant at p=0.2004 (Fig. 2).
Effect of PMB on B Cell Proliferation Activity of BGS
Although the BGS and LPS both had an affect on increasing
the proliferation of B cells, they differ as regards their
origin and structure. Thus, to determine whether their
active ingredients affecting B cells also differed, the response
of the BGS to PMB, an inhibitor of LPS [24], was tested.
Splenic B cells isolated from BALB/c mice were treated
with the BGS, LPS, BGS+PMB, or LPS+PMB, and incubated
for 48 h, and the B cell proliferation was measured using
a 
3
H-TdR incorporation assay. The B cell proliferation
measurement for the sample treated with BGS+PMB
was 13.46±2.24 kcpm, which was slightly lower than the
measurement for the sample treated with the BGS alone at
17.33±0.12 kcpm; however, the statistical difference between
the two BGS samples was insignificant at p=0.1179 (Fig. 3).
In contrast, the B cell proliferation measurement for
the sample treated with LPS+PMB was 4.95±0.069 kcpm,
which was considerably lower than the measurement for the
sample treated with LPS alone, at 23.86±1.52 kcpm. Thus,
the statistical difference was significant at p=0.0172 (Fig. 3).
BGS Induced Proliferation of B Cells Isolated from
C3H/HeJ Mice Lacking Toll-Like Receptor 4
The B cell response to LPS can be induced by binding LPS
with cell-surface Toll-like receptor 4 (TLR4) [7, 16, 27].
Thus, to determine whether the B cell proliferation activity
of the BGS and LPS differed in terms of TLR4 binding, the
effects of the BGS and LPS on splenic B cell proliferation
were tested in C3H/HeJ mice lacking TLR4 [32] and C3H/
HeN mice with intact TLR4. Splenic B cells from C3H/
HeJ mice and C3H/HeN mice were treated with the BGS
or LPS and incubated for 48 h. As shown in Fig. 4, the
proliferation measurement for the splenic B cells from
the C3H/HeJ mice treated with LPS showed a noticeable
decrease at 11.99±1.39 kcpm when compared with the
measurement for the splenic B cells from the C3H/HeN
mice treated with LPS at 22.74±2.12 kcpm, representing a
statistically significant difference at p=0.0021. However,
in the case of treatment with the BGS, the proliferation
measurements for the splenic B cells from the C3H/HeJ mice
and C3H/HeN mice were 18.39±4.22 and 21.30±0.82 kcpm,
respectively, representing a statistically insignificant difference
at p=0.1609.
Change of B Cell Population in Bone Marrow and
Spleen from BGS-Treated BALB/c Mice
To test the effect of the BGS on B cell proliferation in vivo,
BALB/c mice were given a single dose (25 µg/mouse) of
Fig. 3. PMB inhibited B cell proliferation activity of LPS, yet
not that of BGS.
Splenic B cells isolated from BALB/c mice were treated with the BGS
(10 µg/ml), LPS (5 µg/ml), BGS+PMB (5 U/ml), or LPS+PMB. The B cell
proliferation was measured using a 
3
H-TdR incorporation assay. Each
value represents the mean±SD of three trials. *, Statistical significance
compared with “BGS” (p=0.1179). **, Statistical significance compared
with “LPS” (p=0.0172).
Fig. 4. B cell proliferation activity of BGS unaffected by TLR4.
Splenic B cells from C3H/HeN and C3H/HeJ mice were stimulated with
the BGS (10 µg/ml) or LPS (5 µg/ml) for 48 h. The degree of lymphocyte
proliferation was measured using a 
3
H-TdR incorporation assay. Each
value represents the mean±SD of three trials. *, Statistical significance
compared with “C3H/HeN”: p=0.1609 (BGS) and p=0.0021 (LPS).
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the BGS via the peritoneal cavity and then divided into
three subgroups to be sacrificed after 24, 48, and 72 h. The
control group treated with saline was sacrificed after 24 h.
Cells harvested from the bone marrow and spleen were
stained with CD45R/B22O-PE and then analyzed using
FACSCalibur flow cytometry (Fig. 5).
The bone marrow B cell population in the BGS-treated
group sacrificed after 24 h markedly increased to 58.78%
when compared with that in the saline-treated control group
at 37.92%. However, the bone marrow B cell population
decreased to 34.51% and 17.21% in the BGS-treated
groups sacrificed after 48 and 72 h, respectively (Fig. 5A).
The splenic B cell population in the BGS-treated group
sacrificed after 24 h also increased to 44.23% when
compared with that in the saline-treated control group
sacrificed after 24 h at 39.84%. However, in contrast to the
bone marrow B cell population, the splenic B cell
population increased to 54.14% and 52.24% in the BGS-
treated groups sacrificed after 48 and 72 h, respectively
(Fig. 5B).
Target Stage of BGS in B Cell Lineage
To identify the target stage of the BGS during B cell
development, BALB/c mice were treated with a single
dose (25 µg/mouse) of the BGS via the peritoneal cavity,
and then sacrificed after 24 or 48 h. For the control,
another group of BALB/c mice were treated with
saline, and sacrificed after 24 h. Bone marrow cells and
splenocytes were isolated from each group, and MACS
beads used to separate the B cells. The separated B cells
were then stained with FITC-conjugated anti-CD117,
-CD25, -IgM, -IgG, and PE-conjugated anti-AA4.1 and
-IgD, respectively, on B cell lineage-restricted surface
molecules, and finally analyzed using FACSCalibur flow
cytometry, as shown in Figs. 6 and 7.
The transitions in the bone marrow-derived B cell
lineage are shown in Fig. 6. The population of pro B cells
(CD117
+
), a type of B cell progenitor, was 6.89% and
8.01% in the BGS-treated groups sacrificed after 24 and
48 h, respectively, which was higher than the 3.81%
population in the saline-treated control group. The population
of pre B cells (CD25
+
), another type of B cell progenitor,
was 21.71% and 16.34% in the BGS-treated groups sacrificed
after 24 and 48 h, respectively; however, this was not
noticeably different from the 20.82% population in the
saline-treated control group (Fig. 6A).
The population of immature B cells (IgM
+
 and AA4.1
+
)
was 29.4% and 27.2% in the BGS-treated groups sacrificed
after 24 and 48 h, respectively, which was slightly higher
than the 21.2% population in the saline-treated control
Fig. 5. BGS increased B cell population in vivo.
BALB/c mice were treated intraperitoneally with the BGS (25 µg/mouse) or saline. At different time intervals, mice from each group were sacrificed and B
cells isolated from the bone marrow (A) and spleen (B). A FACS analysis was performed based on the staining of CD45R/B220-PE (filled area). Open area:
isotype control. The results are representative of three independent experiments.
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Fig. 6. Effect of BGS on early stage of B lineage cell in vivo.
BALB/c mice were treated intraperitoneally with the BGS (25 µg/mouse) or saline. At different time intervals, mice from each group were sacrificed and B
cells isolated from the bone marrow. A. FACS analysis using antibodies (CD117-FITC, CD25-FITC; filled area). Open area: isotype control. B. FACS
analysis using antibodies (IgM-FITC/AA4.1-PE, IgM-FITC/IgD-PE). C. FACS analysis based on staining of IgG-FITC (filled area). Open area: isotype
control. The results are representative of three independent experiments.
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group. A population increase was also measured for the
mature B cells (IgM
+
 and IgD
+
) at 27.2% and 22.7% in
the BGS-treated groups after 24 and 48 h, respectively,
compared with 18.4% in the saline-treated control group
(Fig. 6B).
In contrast, the population of IgG
+
 B cells showed
different percentage changes to the immature and mature
B cells. After 24 h, the population of IgG
+
 B cells in the
BGS-treated group was 36.5%, which was very similar to
the 34.1% population in the saline-treated control group.
However, the IgG
+
 B cell population in the BGS-treated
group decreased to 26.2% after 48 h (Fig. 6C).
Since the spleen is a secondary lymphoid organ, the
present investigation of the B cell lineage in mouse spleens
treated with the BGS was limited to immature B cells and
mature B cells, as shown in Fig. 7.
The population of splenic immature B cells was 15.2%
in the BGS-treated group after 24 h, which was similar
to the 13.4% population in the saline-treated control
group. However, the splenic immature B cell population
in the BGS-treated group increased to 19.9% after
48 h. Meanwhile, the splenic mature B cell populations
were generally lower in the BGS-treated groups than
in the saline-treated control group. For the saline-treated
control group, the splenic mature B cell population
was 46.2%, whereas it was only 33.6% and 36.9% in
the BGS-treated groups after 24 and 48 h, respectively
(Fig. 7A).
Fig. 7. Effect of BGS on splenic B cell differentiation in vivo.
BALB/c mice were treated intraperitoneally with the BGS (25 µg/mouse) or saline. At different time intervals, mice from each group were sacrificed and B
cells isolated from the spleen. A. FACS analysis using antibodies (IgM-FITC/AA4.1-PE, or IgM-FITC/IgD-PE). B. FACS analysis based on staining of IgG-
FITC (filled area). Open area: isotype control. The results are representative of three independent experiments.
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Finally, the population of splenic IgG
+
 B cells in the
saline-treated control group was 38.6%, whereas in the
BGS-treated groups, the splenic IgG
+
 B cell population
was initially higher at 50.7% after 24 h, and then dropped
to 25.3% after 48 h (Fig. 7B).
BGS Increased Concentration of IgM and IgG In Vivo
To investigate the effect of the BGS on the production
of antibodies in B cells, BALB/c mice were treated with
one dose of the BGS (25 µg/mouse) via the peritoneal
cavity. The BGS-treated mice were then sacrificed after
72 h. The serum was separated from the blood, and
the concentrations of IgM and IgG in the serum were
measured. The concentrations of IgM and IgG for the
saline-treated control group were 0.25±0.15 and 14.26±
2.18 mg/ml, respectively, whereas those for the BGS-
treated group were noticeably higher at 7.38±1.60 and
33.63± 7.92 mg/ml, respectively (Fig. 8).
Adjuvant Effect of BGS
To examine whether the BGS might elicit adjuvant effects
in terms of antigen-specific antibody production, the BGS
was tested in comparison with other adjuvants. Groups
of BALB/c mice were intradermally immunized with
OVA, OVA+BGS, OVA+Al, or OVA+FA once a week for
4 weeks. One week after the last immunization, the OVA-
specific IgG within the blood serum was measured, and the
OVA-specific IgG antibody production found to be higher
in the groups immunized with a mixture of OVA and one of
the adjuvants than in the control group immunized with only
OVA. As shown in Fig. 9, when used as an adjuvant, the
BGS produced almost the same effect as Al, yet less than FA.
DISCUSSION
It has already been reported that microorganisms produce a
great variety of immunomodulators, most of which appear to
increase the growth, differentiation, or activation of T cells,
yet not B cells [33]. Thus, only a few immunomodulators,
such as LPS and polysaccharide from streptococci, are
known to be specific to B cells [12, 15, 22].
The current authors recently isolated a BGS from B.
licheniformis that was identified as a glycoprotein with a
molecular mass of 1,594 kDa [8]. Although the BGS and
LPS do not share a common origin or structure, they both
induce the growth of B cells. Thus, to determine whether
the active ingredients causing the growth of B cells were
similar, the effect of PMB, an LPS inhibitor, on the
functional activity of the BGS was examined, along with
the response of the BGS to TLR4, a receptor of LPS.
When PMB+LPS was added, the growth of splenic B cells
isolated from BALB/c mice was indeed inhibited, whereas
PMB+BGS still induced B cell growth. Similarly, when
splenic B cells from C3H/HeJ mice lacking TLR4 were
used, LPS was unable to induce cell growth, whereas the
BGS successfully induced cell growth. Consequently, in
contrast to LPS, the activities of the BGS were not inhibited
by PMB or TLR4 as a receptor, suggesting that its active
ingredients are different.
When studying the effect of the BGS on the growth of B
cells in vivo, the B cell population was shown to increase
in both bone marrow cells and spleen cells from BALB/c
mice treated with the BGS.
Fig. 8. BGS increased levels of serum IgM and IgG.
BALB/c mice were injected with the BGS (25 µg/mouse) via the
peritoneal cavity. Three days later, 3 mice from each group were sacrificed
and the blood was harvested. The immunoglobulin levels in the sera were
measured by ELISA. Each value represents the mean±SD of three trials. *,
Statistical significance compared with “control”: p=0.0016 (IgM) and p=
0.0083 (IgG).
Fig. 9. BGS affected OVA-specific antibody production as
adjuvant.
BALB/c mice were intradermally immunized with OVA (100 µg/mouse)
or a mixture of OVA and an adjuvant (BGS, Al, or FA) once a week for 4
weeks. One week after the last immunization, mice from each group were
sacrificed and the sera obtained. The levels of OVA-specific IgG in the sera
were measured using ELISA. Each value represents the mean±SD of three
trials. *, Statistical significance compared with “OVA only”: p=0.0044
(OVA+BGS) and p=0.0035 (OVA+Al).
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To examine the BGS target in B cell development, B
cells were harvested and separated from the bone marrow
and spleens of BGS-treated BALB/c mice. These B cells
were then studied using anti-B cell lineage-restricted
surface molecule antibodies. When looking at the B cell
population in the bone marrow, the population of IgG
+
 B
cells showed no change, yet there was a decrease in the
population of pro-B cells and an increase in the populations
of immature B cells and mature B cells. In contrast, when
examining the B cell population in the spleen, the population
of IgG
+
 B cells showed a significant increase when compared
with the slight increase in the population of immature B
cells and decrease in the population of mature B cells.
Thus, when treated with the BGS, the B cell population
increased, due to an increase of immature B cells and
mature B cells. These outcomes also agree with results
from previous studies, which found that B cell progenitors
develop into immature B cells in the bone marrow and
then migrate to the spleen, where they become mature B
cells [3, 4], and that some of the short-lived immature B
cells in the spleen are differentiated and become long-lived
mature B cells [9, 20, 29].
Along with B cell development, V-D-J rearrangements
lead to the formation of clonotypic BCR and surface
expression of IgM molecules [6]. The surface IgM (sIgM)
of B cells initiates class switch recombination (CSR) with
the Cµ gene, a heavy-chain constant region, into Cγ, Cα,
or Cε gene, and then by recombination, each gets to be a
secondary heavy-chain isotype, such as IgG, IgA, or IgE
[13, 26]. In particular, IgG begins to be manifested on the
cell surface during the memory B cell stage, and it is
known to be the most abundant form of Ig isotype amongst
immunoglobulins [2, 10, 28]. In this study, the results
showed no increase in IgG
+
 B cells in the bone marrow of
BGS-treated BALB/c mice, but a high increase of splenic
IgG
+
 B cells, indicating that the BGS may play a role in
the differentiation of mature B cells into IgG
+
 B cells. This
possibility is also supported by the noticeable increase in
the concentrations of IgM and IgG in the blood serum
from the BGS-treated BALB/c mice.
Adjuvants are usually defined as compounds that can
increase and/or modulate the intrinsic lower immunogenicity
of an antigen. Adjuvants are therefore required to assist
vaccines to induce potent and persistent immune responses,
while also providing the additional benefits of reducing the
number of injections and amount of antigen needed [11].
In the present study, the BGS was found to induce the
growth of B cells in vivo, plus it increased the production
of IgM and IgG, indicating that the BGS functions as an
adjuvant. Thus, to investigate the adjuvant effects of the
BGS, BALB/c mice were sensitized with various mixtures
of OVA and the BGS. When the BGS was used as an
adjuvant, high concentrations of anti-OVA antibodies were
found in the mice. Although the adjuvant effect of the BGS
was shown to be less than that of Freund’s adjuvant, which
is a highly effective adjuvant used predominantly in animal
studies [19], the adjuvant effect of the BGS was almost
similar to that of aluminum hydroxide, which is used in
making vaccines for humans [14].
The overall safety concerns, including possible immediate
and long-term side effects, of the BGS as an adjuvant have
not yet been studied. Nonetheless, the antigen-specific
antibody production demonstrated in this study indicates
that the BGS may have potential as a new immuno-
stimulator or adjuvant.
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